Sanofi-aventis doubles syringe production capacity and diversifies vaccine production at the Le Trait Manufacturing Plant
Sanofi-aventis launched its new production units at the Le Trait site in a ceremony attended by Jean-Marie Aline, Mayor of Le Trait, Christophe Bouillon, Member of the French National Assembly for Seine-Maritime, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, and Philippe Luscan, Senior Vice-President for Industrial Affairs, sanofi-aventis.
The Le Trait manufacturing site specializes in producing high-tech sterile injectable products, primarily for export. Over the past 40 years, the site has invested in the most innovative technologies in order to meet patients’ needs and requirements of various international markets, in particular the United States and Japan. The investment in these new production units, one of the largest made on this site since its creation, represents 87 million euros over the past three years.
“Le Trait is one of many examples of sanofi-aventis’ desire to invest in France in order to be able to meet worldwide public health challenges,” said sanofi-aventis Chief Executive Officer Christopher A. Viehbacher. “A cutting-edge technological platform, the Le Trait site produces one million syringes a day and exports close to 90% of its production, 25% of which for the North American market.”
Other news from the department manufacturing
